26 completed, 5 active not recruiting, 2 recruiting, 1 terminated. 17 Phase 1, 15 Phase 2, 1 Early Phase 1, 1 Phase 3.
Follow Triapine: new trials by email Literature Review of Triapine trials Research Report on Triapine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma Biospecimen Collection, Computed Tomography, Intensity-Modulated Radiation Therapy - Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2025-07-30 | 2026-10-21 |
| Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration - Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma | Phase 1 | Recruiting | Northwestern University | 22 | 2024-07-23 | 2026-09-09 |
| Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate - Metastatic Neuroendocrine Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 94 | 2023-08-30 | 2026-07-31 |
| Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy Biopsy Procedure, Biospecimen Collection, Resection - Endometrial Serous Adenocarcinoma | Early Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 12 | 2022-02-08 | 2026-06-11 |
| Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate - Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Neuroendocrine Tumor | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 31 | 2020-07-20 | 2026-09-18 |
| Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer Biospecimen Collection, Brachytherapy, Cisplatin - Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 21 | 2019-09-18 | 2026-10-30 |
| Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers Brachytherapy, Cisplatin, External Beam Radiation Therapy - Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 450 | 2016-05-10 | 2026-10-22 |
| Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer triapine, cisplatin, external beam radiation therapy - Recurrent Cervical Cancer, Recurrent Vaginal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 26 | 2009-07-01 | 2017-11-17 |
| 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery 3-Dimensional Conformal Radiation Therapy, Triapine - Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7 | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2006-12-20 | 2017-08-18 |
| 3-AP in Treating Patients With Advanced or Metastatic Solid Tumors triapine, pharmacological study, laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2006-12-01 | 2013-12-16 |
| 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia fludarabine phosphate, triapine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Phase 2 | Completed | National Cancer Institute (NCI) | 35 | 2006-08-01 | 2015-01-06 |
| 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma gemcitabine hydrochloride, triapine - Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2006-06-01 | 2013-09-30 |
| Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies triapine, laboratory biomarker analysis, external beam radiation therapy - Recurrent Cervical Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2006-03-01 | 2013-01-11 |
| 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer triapine, cisplatin, laboratory biomarker analysis - Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 48 | 2005-07-01 | 2013-01-24 |
| 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer triapine, gemcitabine hydrochloride, laboratory biomarker analysis - Male Breast Cancer, Recurrent Breast Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 68 | 2004-10-01 | 2013-01-16 |
| Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas triapine - Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas | Phase 2 | Completed | National Cancer Institute (NCI) | 116 | 2004-07-01 | 2013-10-08 |
| A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer triapine, gemcitabine hydrochloride, laboratory biomarker analysis - Recurrent Non-small Cell Lung Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 48 | 2004-07-01 | 2013-02-27 |
| 3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma triapine - Kidney Cancer | Phase 2 | Completed | NCIC Clinical Trials Group | 19 | 2004-05-11 | 2023-08-04 |
| 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer gemcitabine hydrochloride, triapine - Pancreatic Cancer | Phase 2 | Completed | University Health Network, Toronto | 26 | 2004-04-01 | 2018-09-14 |
| 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer gemcitabine hydrochloride, triapine - Lung Cancer | Phase 2 | Completed | Cancer Therapeutics Research Group | 31 | 2004-04-01 | 2013-05-15 |
Showing 20 of 34. Sign in to see all of them.
Blast Crisis (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Uterine Cervical Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Congenital Abnormalities (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Myeloid, Accelerated Phase (3) · Leukemia, Myeloid, Acute (3) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (3) · Leukemia, Myelomonocytic, Chronic (3) · Pancreatic Neoplasms (3) · Vaginal Neoplasms (3) · Anemia, Refractory, with Excess of Blasts (2) · Carcinoma, Ovarian Epithelial (2) · Glioblastoma (2)
National Cancer Institute (NCI) (21) · Vion Pharmaceuticals (8) · Cancer Therapeutics Research Group (1) · NCIC Clinical Trials Group (1) · Northwestern University (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University Health Network, Toronto (1)
United States (31) · Canada (3) · Australia (1) · Belgium (1) · Hong Kong (1) · Netherlands (1) · Puerto Rico (1) · Singapore (1) · South Korea (1) · United Kingdom (1)
Mario Sznol, MD (8) · Charles Kunos (2) · George Wilding (2) · Tanios Bekaii-Saab (2) · Allyson Ocean (1) · Ann Mauer (1) · Anne Traynor (1) · Brigette Ma, MD (1) · Charles A Leath (1) · James Stewart (1) · Jennifer Knox, MD (1) · Judith E. Karp, MD (1) · Judith Karp (1) · Karan Dixit, MD (1) · Kyle Holen (1)
PMID 17393073, PMID 17640728, PMID 20981545, PMID 22105720, PMID 22541066, PMID 24362550, PMID 27878356, PMID 29868473, PMID 31681600, PMID 36185311, PMID 39673591, PMID 42518206
N01CM62205 (2), P30CA006973 (2), U01CA062491 (2), U01CA062502 (2), U01CA062505 (2), U01CA070095 (2), U01CA076576 (2), UM1CA186712 (2), N01CM62201 (1), N01CM62204 (1), P30CA014520 (1), P30CA016058 (1), P30CA043703 (1), P30CA060553 (1), U01CA069852 (1)